Effect of rhTPO on chemotherapy-induced thrombocytopenia in elderly patients with acute myeloid leukemia

Abstract

Objective To analyze the safety and therapeutic effect of recombinant human thrombopoietin (rhTPO) on chemotherapy-induced thrombocytopenia in senile patients with acute myeloid leukemia (AML). Methods Fifty elderly patients with AML admitted to People’s Hospital of Zhengzhou University from June 2016 to June 2018 were selected as research objects. According to whether rhTPO was used to treat thrombocytopenia after chemotherapy, they were divided into treatment group (28 cases) and control group (22 cases). When levels of platelets was below 20×109/L, patients of the two groups were infused with blood platelets continually. Recovery time of platelet counts and adverse reactions were compared between the two groups. Results The time of platelet count of treatment group recovered to≥20×109/L was (6.1±1.8) d, and the time of control group was (6.7±2.1) d, however, the difference was not statistically significant (P>0.05). The time of platelets count recovered to≥50×109/L and normal (≥100×109/L) in treatment group were (9.9±1.5)d and (11.4±2.4)d, respectively; and they were (11.5±1.6)d and (14.8±3.2)d in control group; the difference was statistically significant between the two groups (P<0.05). Patients in treatment group were infused with platelets (5.8 ± 1.7)U, and patients in control group were infused with(7.4±1.8)U of platelets, moreover, the difference was statistically significant (P<0.05). No significant adverse reactions occurred during the treatment with rhTPO. Conclusions rhTPO is effective in the treatment of thrombocytopenia after chemotherapy in elderly patients with AML, with good tolerance and reduced platelet transfusion. Key words: Recombinant human thrombopoietin; Elderly; Chemotherapy-induced thrombocytopenia